These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6430322)

  • 21. Cyclandelate in the treatment of senility: a controlled study.
    Capote B; Parikh N
    J Am Geriatr Soc; 1978 Aug; 26(8):360-2. PubMed ID: 353121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of effect of cyclandelate in peripheral arterial disease.
    Vyden JK; Nagasawa K; Kanazawa M; Rose HB; Seino Y; Groseth-Robertson MF; Lander EB; Elconin SB
    Angiology; 1984 Jan; 35(1):1-11. PubMed ID: 6364892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of a combined anti-ischemic and anticholinergic substance with antidepressant properties.
    Brasseur R
    Angiology; 1978 Feb; 29(2):121-32. PubMed ID: 646177
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.
    Sourander L; Blakemore CB
    Angiology; 1978 Feb; 29(2):133-8. PubMed ID: 347985
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of early diabetic retinopathy with cyclandelate.
    Cunha-Vaz JG; Reis Fonseca J; Hagenouw JR
    Br J Ophthalmol; 1977 Jun; 61(6):399-404. PubMed ID: 326306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.
    Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L
    Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation.
    Rao DB; Georgiev EL; Paul PD; Guzman AB
    J Am Geriatr Soc; 1977 Dec; 25(12):548-51. PubMed ID: 336670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 31. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy.
    De Leeuw IH; Van Rooy P; Moeremans M; Driessens M
    Drugs; 1987; 33 Suppl 2():125-30. PubMed ID: 3304951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 34. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of rubber seed oil on the development and regression of experimental atherosclerosis of the aorta in rabbits (author's transl)].
    Liu CR; Tang CC; Yang L
    Zhonghua Xin Xue Guan Bing Za Zhi; 1981 Mar; 9(1):54-7. PubMed ID: 7261894
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency.
    Smith WL; Lowrey JB; Davis JA
    Curr Ther Res Clin Exp; 1968 Dec; 10(12):613-8. PubMed ID: 4972756
    [No Abstract]   [Full Text] [Related]  

  • 37. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 38. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 39. [New determination of cyclandelate in plasma (author's transl)].
    Andermann G; Dietz M; Mergel D
    J Pharm Belg; 1979; 34(4):233-7. PubMed ID: 501515
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.